Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Bilello

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Infectious Diseases|March 1, 1995
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoproteinJ A Bilello, P A Bilello, M Prichard, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studiesJ A Bilello, G Bauer, M N Dudley, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytesJ A Bilello, J J Kort, C MacAuley, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1995
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitroJ A Bilello, P A Bilello, J J Kort, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1987
Transmission in NFS/N mice of the heritable spongiform encephalopathy associated with the gray tremor mutationP M Hoffman, R G Rohwer, C MacAuley, et al.
The Journal of Infectious Diseases|March 10, 2001
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variableG L Drusano, J A Bilello, S L Preston, et al.
Antiviral Research|December 1, 1991
Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDSJ L Eiseman, R A Yetter, T N Fredrickson, et al.
AIDS (London, England)|May 1, 1996
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)D S Stein, D G Fish, J A Bilello, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Pharmacodynamics of abacavir in an in vitro hollow-fiber model systemG L Drusano, P A Bilello, W T Symonds, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitroG L Drusano, D Z D'Argenio, W Symonds, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|March 1, 1995
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoproteinJ A Bilello, P A Bilello, M Prichard, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studiesJ A Bilello, G Bauer, M N Dudley, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytesJ A Bilello, J J Kort, C MacAuley, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1995
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitroJ A Bilello, P A Bilello, J J Kort, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1987
Transmission in NFS/N mice of the heritable spongiform encephalopathy associated with the gray tremor mutationP M Hoffman, R G Rohwer, C MacAuley, et al.
The Journal of Infectious Diseases|March 10, 2001
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variableG L Drusano, J A Bilello, S L Preston, et al.
Antiviral Research|December 1, 1991
Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDSJ L Eiseman, R A Yetter, T N Fredrickson, et al.
AIDS (London, England)|May 1, 1996
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)D S Stein, D G Fish, J A Bilello, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Pharmacodynamics of abacavir in an in vitro hollow-fiber model systemG L Drusano, P A Bilello, W T Symonds, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitroG L Drusano, D Z D'Argenio, W Symonds, et al.
Pageof 4